Several novel agents, including idelalisib (Zydelig), belinostat (Beleodaq), and ibrutinib (Imbruvica), have shown promise across multiple types of non-Hodgkin lymphoma (NHL). These new therapies, among others, have changed the treatment paradigm for NHL, significantly improving outcomes for patients.
John Radford, MD, Teenage Cancer Trust Professor of Teenage and Young Adult Cancer at the University of Manchester and Director of Research at the Christie NHS Foundation Trust, has focused his research on new treatments of lymphoma and monitoring their efficacy using novel biomarkers and the late effects of both standard and novel treatments in NHL.
